Skip to main content

Table 1 REMAP-COVID domains and arms. Additional domains can be found at www.remapcap.org

From: Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations

Domain Arms
Antivirala Hydroxychloroquine Usual care  
Corticosteroidsa Low dose hydrocortisone Moderate dose hydrocortisone Usual care
Immunoglobulinb Convalescent plasma Usual care Monoclonal antibodies
Therapeutic Anticoagulationb Full dose anticoagulation (DVT/PE) Thromboprophylaxis  
Vitamin Cb High dose vitamin C Usual care  
Immune Modulation 2 (IM2)b,c Eritoranc Apremilastc Usual care
Platelet Inhibitiond P2Y12 inhibitor Aspirin Usual care
Statinsd Simvastatin Usual care  
ACE2 RAS Modulationd ACE inhibitor ARBe Usual care
Mechanical Ventilationd Protocolized mechanical ventilation Usual care  
  1. DVT/PE deep vein thrombosis/pulmonary embolus, IND Investigational New Drug, IRB Institutional Review Board, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
  2. aDomain closed in the USA
  3. bDomain actively enrolling in the USA, in partnership with the ATTACC and ACTIV4a (therapeutic anticoagulation), and LOVIT (Vitamin C) trials
  4. cEnrolling as an IND domain under FDA oversight
  5. dProtocol in development or pending activation
  6. eA fourth arm of an ARB with a chemokine receptor-2 inhibitor may also be offered